undamentalytics Newsletter
Sign in

Amarin Corp plc\uk revenue

Amarin Corp plc\uk's revenue was $214m in fiscal 2025, down 6.5% on the year before. Since fiscal 2013 ($26.4m) it has grown at a compound 19.1% a year. Over the last twelve months it was $176m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue265482130181229430614583369307229214176
Growth on the year before—+105.7%+50.8%+59.1%+39.2%+26.6%+87.5%+42.9%−5.0%−36.7%−16.9%−25.5%−6.5%—
Gross profit143454961361753344834622421668112172
Gross margin54.8%62.2%65.9%73.6%75.2%76.2%77.7%78.6%79.2%65.7%53.9%35.6%56.6%40.9%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $183M 85.5% ▼ 10.7%
Licensing and Royalty $30.9M 14.5% ▲ 28.6%

From Amarin Corp plc\uk's 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Amarin Corp plc\uk $176m -22.3% -18.3%
Cronos Group Inc. $179m 37.5% 30.3%
Kamada LTD $180m 12.1% —
Biote Corp. $184m -7.8% 0.5%
Organigram Global Inc. $185m 57.8% —
Heron Therapeutics, Inc. $151m 1.0% 8.6%

Compare with peers

Head to head: AMRN vs CRONAMRN vs KMDAAMRN vs BTMDAMRN vs HRTX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Amarin Corp plc\uk's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amarin Corp plc\uk.